Compounds > rasagiline
Page last updated: 2024-09-03

rasagiline and Atherosclerotic Parkinsonism

rasagiline has been researched along with Atherosclerotic Parkinsonism in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19901 (20.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's1 (20.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Date, AA; Kalaria, D; Kalia, Y; Patel, P; Patravale, V; Pol, A1
Arami, MA; Ayromlou, H; Najmi, S1
Amit, T; Mandel, S; Sagi, Y; Youdim, MB1
Tipton, KF; Youdim, MB1
Finberg, JP; Youdim, MB1

Other Studies

5 other study(ies) available for rasagiline and Atherosclerotic Parkinsonism

ArticleYear
Microemulsion-based gel for the transdermal delivery of rasagiline mesylate: In vitro and in vivo assessment for Parkinson's therapy.
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2021, Volume: 165

    Topics: Administration, Cutaneous; Administration, Oral; Animals; Biological Availability; Disease Models, Animal; Emulsions; Feasibility Studies; Humans; Hydrogels; Indans; Locomotion; Male; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Rabbits; Rats; Rotenone; Skin; Skin Tests

2021
Hemiparkinsonism-hemiatrophy syndrome.
    Archives of Iranian medicine, 2011, Volume: 14, Issue:2

    Topics: Adult; Antiparkinson Agents; Atrophy; Benzothiazoles; Biperiden; Carbidopa; Cerebral Cortex; Cerebral Ventricles; Dopamine Agonists; Drug Combinations; Humans; Indans; Levodopa; Magnetic Resonance Imaging; Male; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Pramipexole; Tomography, X-Ray Computed

2011
Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism.
    Neurobiology of disease, 2007, Volume: 25, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blotting, Western; Cell Survival; Cells, Cultured; DNA, Complementary; Dopamine; Dopamine Agents; Enzyme Activation; Gene Expression Regulation; Immunohistochemistry; Indans; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase Inhibitors; Nerve Degeneration; Nerve Tissue Proteins; Neuroprotective Agents; Parkinson Disease, Secondary; Receptor Protein-Tyrosine Kinases; Signal Transduction; Substantia Nigra

2007
Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease.
    Parkinsonism & related disorders, 2002, Volume: 8, Issue:4

    Topics: Animals; Behavior, Animal; Corpus Striatum; Dose-Response Relationship, Drug; Drug Synergism; Indans; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Phenethylamines; Psychotropic Drugs; Rats; Rats, Sprague-Dawley; Selegiline; Stereotyped Behavior

2002
MAO type B inhibitors as adjunct to L-dopa therapy.
    Advances in neurology, 1987, Volume: 45

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alkynes; Animals; Brain; Drug Therapy, Combination; Humans; Indans; Isoenzymes; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Receptors, Dopamine; Selegiline; Structure-Activity Relationship; Tyramine

1987